In addition, the monovalent inhibitor TD139 (Galecto Biotech, Copenhagen, Denmark), showing an excellent affinity both to Gal-1 and Gal-3 (0.22 μM ± 0.05 for Gal-1 versus 0.068 μM ± 0.01 for Gal-3 from ITC determination) [4,5], has ended Phase Ib/IIa clinical trials for the treatment of idiopathic pulmonary fibrosis [8]. Here, LGALS3 is linked to idiopathic pulmonary fibrosis.